Scott R. Silverman Resumes the Role of Chief Executive Officer of VeriChip Corporation
27 8월 2009 - 10:19PM
Business Wire
VeriChip Corporation (NASDAQ:CHIP) ("VeriChip" or the
"Company"), a provider of radio frequency identification (RFID)
systems for healthcare and patient-related needs, announced today
that Scott R. Silverman, its current executive chairman, has
resumed the role of CEO of the Company. Earlier this week, the
Company announced the re-launch of its Health Link electronic
personal health record (PHR).
Driving the re-launch of the Health Link PHR is the Company's
belief that identification technologies and tools will become more
prevalent to protect consumers and businesses. The Company believes
its long-standing history and expertise in patient identification
and personal health records can be the starting point of a broad
array of these technologies and tools.
Commenting on his return to CEO, Mr. Silverman stated, "I am
pleased to return to the day-to-day operations at the Company. With
healthcare playing a leading role on the national stage, protecting
one's personal information is more important than ever. Our Health
Link PHR, which has a history dating back to 2004, can form the
foundation of a business built to protect you and your critical
personal information."
Mr. Silverman, who beneficially owns approximately 6.8 million
shares of the Company, purchased the majority ownership position in
November 2008. He will maintain his role as executive chairman of
the Company's board of directors. Mr. Silverman, who has not taken
cash compensation since the second half of 2008, will continue to
not take cash compensation for the remainder of 2009.
About VeriChip Corporation
VeriChip Corporation, headquartered in Delray Beach, Florida,
has developed the VeriMed™ Health Link System for rapidly and
accurately identifying people who arrive in an emergency room and
are unable to communicate. This system uses the first
human-implantable passive RFID microchip, cleared for medical use
in October 2004 by the United States Food and Drug
Administration.
For more information on VeriChip, please call 1-800-970-2447, or
e-mail info@verichipcorp.com. Additional information can be found
online at www.verichipcorp.com.
Statements about VeriChip’s future expectations, including its
belief that identification technologies and tools will become more
prevalent to protect consumers and businesses and its belief that
its long-standing history and expertise in patient identification
and personal health records can be the starting point of a broad
array of these technologies and tools, and all other statements in
this press release other than historical facts are “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934, and as
that term is defined in the Private Litigation Reform Act of 1995.
Such forward-looking statements involve risks and uncertainties and
are subject to change at any time, and VeriChip’s actual results
could differ materially from expected results. Additional
information about these and other factors that could affect the
Company’s business is set forth in the Company’s various filings
with the Securities and Exchange Commission, including those set
forth in the Company’s 10-K filed on February 12, 2009, under the
caption “Risk Factors.” The Company undertakes no obligation to
update or release any revisions to these forward-looking statements
to reflect events or circumstances after the date of this statement
or to reflect the occurrence of unanticipated events, except as
required by law.
Verichip (MM) (NASDAQ:CHIP)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Verichip (MM) (NASDAQ:CHIP)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024